{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:18:44Z","timestamp":1775841524579,"version":"3.50.1"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012175","name":"Zhejiang Traditional Chinese Medicine Administration","doi-asserted-by":"publisher","award":["2024-XK-32, 2022ZB172, GZS2012013"],"award-info":[{"award-number":["2024-XK-32, 2022ZB172, GZS2012013"]}],"id":[{"id":"10.13039\/501100012175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Nintedanib, a small molecule multi-target tyrosine kinase inhibitor, can block the fibrosis process and slow disease progression. Acute thrombocytopenia and fibrinogen reduction caused by nintedanib is a rare clinical event, with few studies reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We report the case of an 89-year-old male diagnosed with advanced renal cell carcinoma who developed immune-related interstitial lung disease after treatment with sintilimab injection combined with axitinib. After prescribed nintedanib treatment, the patient\u2019s platelet count decreased from 241\u00d710 \u03bc g\/L to 49\u00d710 \u03bc g\/L and fibrinogen decreased from 5.61 g\/L to 0.76 g\/L. Based on the patient\u2019s medical history, laboratory test results, and examination results, the diagnosis was made that it was nintedanib-induced reduction in platelet and fibrinogen levels. After discontinuation of nintedanib, the patient\u2019s platelets and fibrinogen returned to normal, and no further reduction in platelets and fibrinogen was observed during the follow-up period. This case report suggests to physicians that if there is an unexplained decrease in platelet and fibrinogen levels during nintedanib treatment, nintedanib-induced factors should be considered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Thrombocytopenia and fibrinogens abnormal are rare but serious adverse effect of nintedanib. This case highlights the importance of early recognition and monitoring of platelet counts and coagulation function in patients receiving nintedanib. Suspect drug discontinuation and active supportive care are essential. Further research is needed to elucidate the underlying mechanisms and then make corresponding treatment recommendations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1561440","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T04:12:06Z","timestamp":1754539926000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute thrombocytopenia and fibrinogen reduction occurring after nintedanib treatment for immune checkpoint inhibitor-related pneumonia: a case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Jian","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexiang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000526141","article-title":"Risk factors for immune checkpoint inhibitor-related pneumonitis in cancer patients: A systemic review and meta-analysis","volume":"101","author":"Zhou","year":"2022","journal-title":"Respiration"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in north carolina","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.628","article-title":"Thrombocytopaenia during nintedanib treatment in a patient with idiopathic pulmonary fibrosis","volume":"8","author":"Ochi","year":"2020","journal-title":"Respirol Case Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59050999","article-title":"Drug-induced thrombocytopenia due to nintedanib during treatment of idiopathic pulmonary fibrosis","volume":"59","author":"Dumic","year":"2023","journal-title":"Med (Kaunas)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.11.027","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: A position paper from the fleischner society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.13699\/j.cnki.1001-6821.2022.10.023","article-title":"Research status on the drug-induced lung injury","volume":"38","author":"Fan","year":"2022","journal-title":"Chin J Clin Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.87288","article-title":"Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis","volume":"12","author":"Yanagihara","year":"2024","journal-title":"Elife"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2200380","DOI":"10.1183\/13993003.00380-2022","article-title":"Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial","volume":"60","author":"Otsubo","year":"2022","journal-title":"Eur Respir J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12890-019-0920-9","article-title":"Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer\/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report","volume":"19","author":"Yamakawa","year":"2019","journal-title":"BMC Pulm Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e37808","DOI":"10.1097\/MD.0000000000037808","article-title":"A retrospective study of combination therapy with glucocorticoids and pirfenidone for PD-1 inhibitor-related immune pneumonitis","volume":"103","author":"Li","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01452-5","article-title":"Safety of nintedanib in patients with idiopathic pulmonary fibrosis: global pharmacovigilance data","volume":"37","author":"Lasky","year":"2020","journal-title":"Adv Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01487-0","article-title":"Nintedanib: A review in fibrotic interstitial lung diseases","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1938","article-title":"Risk of thrombocytopenia with platelet-derived growth factor receptor kinase inhibitors in cancer patients: A systematic review and meta-analysis of phase 2\/3 randomized, controlled trials","volume":"61","author":"Liu","year":"2021","journal-title":"J Clin Pharmacol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1561440\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T04:12:09Z","timestamp":1754539929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1561440\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":14,"alternative-id":["10.3389\/fonc.2025.1561440"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1561440","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"article-number":"1561440"}}